1 / 5

The Car T Cell Therapy Market  To Witness Technological Upsurge In The Forecast

CAR T-cell therapy is based on a personalized approach and thus, ensures improved patient compliance that tends to changing the perception towards its adoption. Prominently driven by this, global CAR T-cell therapy market is expected to reach the revenues worth US$ 800 Mn by the end of 2019 and would exhibit spectacular growth through 2026, at an estimated CAGR of 18%.<br><br>

Archit
Télécharger la présentation

The Car T Cell Therapy Market  To Witness Technological Upsurge In The Forecast

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Car T Cell Therapy Market To Witness Technological Upsurge In The Forecast Period Report Id : PMRREP28264 Category : Life Science & Healthcare ©2020 Persistence Market Research, All Rights Reserved

  2. About Persistence Market Research Customized Research Persistence Market Research(Persistence Market Research) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. Persistence Market Research is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Syndicated Research Investment Research Social Media Research Research Capabilities Sector Coverage • Automotive and Transportation • Electronics, Semiconductor, and ICT • Retail and Consumer Products • Industrial Automation and Equipment • Customized Research • Syndicated Research • Investment Research • Social Media Research • Chemicals & Materials • Food and Beverages • Services and Utilities • Energy, Mining, Oil, and Gas Subscription Information For detailed subscription information please contact Website: www.persistencemarketresearch.com For sales queries or new topics email us on: sales@persistencemarketresearch.com

  3. North America to remain dominant in the global parenteral medical nutrition market Key Takeaways – CAR T-cell Therapy Market Study Increasing product availability, improving reimbursement scenarios, and expanding patient pool of relapsed cancer will remain the key factors shaping CAR T-cell therapy market landscape in Europe. High price point of CAR T-cell therapy continues to hamper its adoption for relapsed cancer treatment. To tackle this issue, Novartis AG, the pioneering CAR T-cell therapy manufacturer agreed for discounted pricing of its products in the U.K. after striking the deal with National Health Service (NHS). In October 2018, NHS also signed a deal with CAR T-cell therapy Yescarta manufacturer, Gilead Sceinces Inc. CAR T-cell therapy agent, bb2121, is in the late stage of clinical development for treatment of multiple myeloma. It would be the first CAR T-cell therapy agent approved for multiple myeloma treatment. Axicabtageneciloleucel is projected to be a high selling product owing to its comparatively easier and glitch-free manufacturing procedure, compared to tisagenlecleucel.  Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/28264

  4. Market Segmentation Access Full Report @ https://www.persistencemarketresearch.com/checkout/28264

More Related